Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 555-560

  Konno, Satomi ^a   Hirooka, Yoshitaka ^a   Araki, Shuichiro ^a   Koga, Yasuaki ^a   Kishi, Takuya ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Brain; Ca channel blocker; Oxidative stress; Sympathetic nervous system

Indexed keywords

AZELNIDIPINE; COPPER ZINC SUPEROXIDE DISMUTASE; HYDRALAZINE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NORADRENALIN; SUPEROXIDE DISMUTASE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DRUG DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART RATE; HYPERTENSION; MALE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE; SUPERIOR COLLICULUS; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; DIET THERAPY; DISEASE MODEL; DRUG EFFECT; MEDULLA OBLONGATA; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; SPONTANEOUSLY HYPERTENSIVE RAT; URINE; WISTAR KYOTO RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; HEART RATE; HYDRALAZINE; HYPERTENSION; MALE; MEDULLA OBLONGATA; NADPH OXIDASE; NOREPINEPHRINE; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STROKE; SUPEROXIDE DISMUTASE; SYMPATHETIC NERVOUS SYSTEM; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 59449089843     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318192690e     Document Type: Article

References (34)

1. Mancia G, De Backer G, Dominiczak A, et al, for the ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
2. Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 7-complete version. Hypertension. 2003;42:1206-1252.
3. Alderman MH, Cohen H, Roque R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349:594-598.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288: 2981-2997.
5. Julius S, Kjeldsen SE, Weber M, et al, for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-2031.
6. Huang BS, Leenen FH. Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2003;42:153-160.
7. Huang BS, Murzenok PP, Keenen FH. Sympathoinhibitory and depressor responses to long-term infusion of nifedipine in spontaneously hypertensive rats on high-salt diet. J Cardiovasc Pharmacol. 2000;36: 704-710.
8. Hirooka Y, Kimura Y, Nozoe M, et al. Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2006;29: 49-56.
9. Lindqvist M, Kahan T, Melcher A, et al. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens. 2007;25:169-175.
10. Iigaya K, Kumagai H, Onimaru H, et al. Novel axonal projection from the caudal end of the ventrolateral medulla to the intermediolateral cell column. Am J Physiol. 2007;292:R927-R936.
11. Kimura Y, Hirooka Y, Sagara Y, et al. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. Clin Exp Hypertens. 2007; 29:13-21.
12. Kishi T, Hirooka Y. Sympatho-inhibitory effects of azelnidipine in the patients with essential hypertension. Ther Res. 2007;28:711-716.
13. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994;74:323-364.
14. Miyawaki T, Goodchild AK, Pilowsky PM. Evidence for a tonic GABA-ergic inhibition of excitatory respiratory-related afferents to presympathetic neurons in the rostral ventrolateral medulla. Brain Res. 2002;924: 56-62.
15. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-346.
16. Kishi T, Hirooka Y, Kimura Y, et al. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation. 2004;109:3257-3262.
17. Kishi T, Hirooka Y, Sakai K, et al. Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension. 2001;38:896-901.
18. Kishi T, Hirooka Y, Ito K, et al. Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;39: 264-268.
19. Kishi T, Hirooka Y, Kimura Y, et al. Overexpression of eNOS in RVLM improves impaired baroreflex control of heart rate in SHRSP. Hypertension. 2003;41:255-260.
20. Kishi T, Hirooka Y, Shimokawa H, et al. Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens. 2008;30:1-9.
21. Xie T, Plagge A, Gavrilova O, et al. The alternative stimulatory G protein α-subunit XLαs is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem. 2006;281: 18989-18999.
22. Gao L, Wang W, Li YL, et al. Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. Am J Physiol. 2005;288:H2271-H2279.
23. Tanaka M, Umemoto S, Kawahara S, et al. Angiotensin II type 1 receptor antagonist and angiotensin-converting enzyme inhibitor altered the activation of Cu/Zn-containing superoxide dismutase in the heart of stroke-prone spontaneously hypertensive rats. Hypertens Res. 2005;28: 67-77.
24. Romero RM, Canuelo A, Lara EM, et al. Aging affects but does not eliminate the enzymatic antioxidative response to hypoxia/reoxygenation in cerebral cortex. Exp Gerontol. 2006;41:25-31.
25. Nozoe M, Hirooka Y, Koga Y, et al. Inhibition of Rac1-derived reactive oxygen species in nucleus tractus solitarius decreases blood pressure and heart rate in stroke-prone spontaneously hypertensive rats. Hypertension. 2007;50:62-68.
26. Yamagishi S, Inagaki Y, Nakamura K, et al. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidant properties. J Cardiovasc Pharmacol. 2004;43:724-730.
27. Umemoto S, Tanaka M, Kawahara S, et al. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2004;27:877-885.
28. Masumoto K, Takeyasu A, Oizumi K, et al. Studies of novel 1,4-dihydropyridine Ca antagonist CS-905.I. Measurement of partition coefficient (LogP) by high performance liquid chromatography (HPLC). Yakugaku Zasshi. 1995;115:213-220.
29. Tanaka T, Nangaku M, Miyata T, et al. Blockade of calcium influx through L-type calcium channels attenuate mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol. 2004;15: 2320-2334.
30. Kobayashi T, Kuroda S, Tada M, et al. Calcium-induced mitochondrial swelling and cytochrome c release in the brain: its biochemical neuronal injury. Brain Res. 2003;960:62-70.
31. Cano-Abad MF, Villarroya M, Garcia AG, et al. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J Biol Chem. 2001;276:39695-39704.
32. Yamanaka S, Tsutsumi T, Shiraishi J, et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol. 2003;41:870-878.
33. Panin VL, Kamiya T, Zhang H, et al. Prevention of neuronal damage by calcium channel blockers with antioxidant effects after transient focal ischemia in rats. Brain Res. 2007;1176:143-150.
34. Hesse C, Charkoudian N, Liu Z, et al. Baroreflex sensitivity inversely correlates with ambulatory blood pressure in healthy normotensive humans. Hypertension. 2007;50:41-46.